Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit?

Table 1

Studies reviewed.

Year	Author	Indication		Median wear time	Maximal wear time	Number of appropriate shocks	Median time to the first appropriate shock	Maximal time to the first appropriate shock
2010	Collins et al. [14]	Any (≤18 years of age)	81	29	531	0	No shocks	No shocks
		Any (18–21 years of age)	103	35	499	5
2010	Chung et al. [15]	Any	3569	36	1590	80
2010	Klein et al. [24]	Any	354	106^a	>7 years	21
2010	Dillon et al. [17]	Any	2105	36	365	54
2012	Kao et al. [23]	Heart failure^b	82	64	277	0	No shocks	No shocks
2013	Epstein et al. [22]	ICM	8453	57		309	9	>9 months
2014	Wan et al. [21]	Hemodialysed patients^c	75	62.9^a	308	136
2014	Tanawuttiwat et al. [20]	Device infection	97	21^d		4	23	38
2015	Singh et al. [19]	ICM	271	53		6	34	45
		NICM	254	71		0	No shocks	No shocks
2016	Lamichhane et al. [18]	HFrEF^e	220	394	2013	13
2016	Wäßnig et al. [13]	Any	6043	59	163	^f
2017	Erath et al. [25]	Any	1102	54	166	8
2017	Sasaki et al. [26]	Any	50	16	171	6	12	30
2017	Duncker et al. [16]	PPCM	49	120^a		5	68	124^g

^aReported as a mean; ^bdefined by own specific criteria; ^conly patients with SCD events included; ^dmedian calculated for only 80 study patients; ^ewear time always >90 days; ^f89% of treatments occurred in the first 90 days; ^gcalculated from the time of diagnosis and not from the beginning of device therapy; not reported. Time is presented in days.